Quality Management Systems

Working Group Chair(s)
Melissa Torres
Food and Drug Administration (FDA)
United States of America
Mairead Finucane
European Commission
European Union
Membership
Regulators and Industry Stakeholders
Status
Current

Quality management systems and risk management activities are integral principles to ensuring the design and manufacture of safe and effective medical devices. ISO 13485 outlines the quality management system requirements that can be used by an organization involved in one or more stages of the life-cycle of a medical device. ISO 14971 specifies terminology, principles and a process for risk management of medical devices, that are intended to assist manufacturers of medical devices to identify the hazards associated with the medical device, to estimate and evaluate the associated risks, to control these risks, and to monitor the effectiveness of the controls. GHTF Study Group 3 developed several documents to support ISO 13485 and ISO 14971 including documents covering Risk Management, Process Validation, Corrective and Preventive Action, and Control of Products and Services Obtained from Suppliers. These existing GHTF documents were developed between 2004 – 2010 and contain outdated QMS and risk management principles. The QMS Working Group intends to update these documents to ensure they are aligned with the current versions of ISO 13485 and ISO 14971.

 

Participants

Dr Paulyne Wairimu
Pharmacy Board of Kenya
Frank Laban
Zambia Medicines Regulatory Authority

Mariela Aranda
National Administration of Drugs, Food and Medical Devices (ANMAT)

Dr Jan Michalicek
Therapeutic Goods Administration (TGA)
Zoe Barrand
Therapeutic Goods Administration (TGA)

Mariana Denardin Klein
Brazilian Health Regulatory Agency (ANVISA)
Mr Jangley Bahia Costa
Brazilian Health Regulatory Agency (ANVISA)

Erin Hartree-Novak
Health Canada
Fred Hamelin
Health Canada

Maria-Chiara Orlandi
European Commission
Peter Qvist
Danish Medicines Agency
Rainer Edelhäuser
Central Authority of the Länder for Health Protection with regard to Medicinal Products and Medical Devices

Mamatha Sg
GE Healthcare
Mia Spiegelman
Medtech Canada
Naoki Morooka
Shimadzu Corporation

Abdullatif Al Watban
Saudi Food and Drug Authority
Annie Qiman Yin
Roche Diagnostics, China

Gabriele Nebl
Global Regulatory Policy and Intelligence, Roche Diagnostics
Hideki Asai
Med-Mirai Inc
Nadeen Ali-Khan
Johnson & Johnson Medical

Kazuo Oguri
Ministry of Health, Labour and Welfare (MHLW)
Manabu Miyake
Pharmaceuticals and Medical Devices Agency (PMDA)
Noriaki Tokunaga
Pharmaceuticals and Medical Devices Agency (PMDA)

Ariffin Aidahwaty
Medical Device Authority (MDA) Ministry of Health, Malaysia.
Yaakop Salbiah
Medical Device Authority (MDA) Ministry of Health, Malaysia.

Alejandra Nicoll Rivera Montoya 
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia
Elizabeth Peña Ardila
Instituto Nacional de Higiene Rafael Rangel (INHRR), Venezuela
Karina Lucía Flores de Barriere
Dirección Nacional de Medicamentos (DNM), El Salvador
Mábel Constanza Barbosa Romero
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia
Yusniel Pérez Reyes
Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED) Cuba)

Tan Yuhua
Health Sciences Authority (HSA)

Dr Dimakatso Mathibe
South African Health Products Regulatory Authority (SAHPRA)
Khanyisile Nkuku
South African Health Products Regulatory Authority (SAHPRA)
Lydia Motlogelwa
South African Health Products Regulatory Authority (SAHPRA)

Seungbum Ko
Ministry of Food and Drug Safety (MFDS)
Sunny Park
Ministry of Food and Drug Safety (MFDS)
Yumi Jin
Ministry of Food and Drug Safety (MFDS)

Janine Leese
Swissmedic
Maria Bofan
Swissmedic
Ulrike Meyer
Swissmedic

Shun-Hao Tsao
Taiwan Food and Drug Administration (TFDA)

Rob Higgins
Medicines and Healthcare products Regulatory Agency (MHRA)
Sharon Knight
Medicines and Healthcare products Regulatory Agency (MHRA)
Suzanne Fuller
Medicines and Healthcare products Regulatory Agency (MHRA)